Discovery and engineering of novel anti-IgE disruptive inhibitors
新型抗 IgE 破坏性抑制剂的发现和工程设计
基本信息
- 批准号:10495213
- 负责人:
- 金额:$ 19.68万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-24 至 2023-08-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAffinityAllergensAllergicAllergic DiseaseAllergic ReactionAnaphylaxisAnkyrin RepeatAnti-Allergic AgentsAntibodiesAntigen PresentationAntigensAsthmaB-LymphocytesBasophilsBindingBiochemicalCellsClinical PathwaysClinical ResearchComplexDataDiagnosisDissociationDrug HypersensitivityEffector CellEligibility DeterminationEngineeringEpithelial CellsExhibitsFc ImmunoglobulinsFoodFood HypersensitivityFoundationsFutureHealthHumanHypersensitivityIgEIgE ReceptorsImmuneImmune responseImmune systemImmunizationImmunoglobulin GIncidenceIndividualInflammatoryInflammatory ResponseKineticsLibrariesLigandsLlamaMediatingMediator of activation proteinMethodsMolecular ConformationNutsPathway interactionsPeripheralPollenPopulationProcessProductionProteinsProtocols documentationPublishingShellfishStainsStructureSudden DeathTestingTherapeuticTissuesTranslatingUnited StatesUrticariaVariantYeastsallergic responseanti-IgEantibody inhibitorbasechronic rhinosinusitisclinical developmentdesensitizationdesignexperimental studyflexibilityhuman diseasehuman morbidityimprovedinhibitormast cellnanobodiesnovelnovel strategiesomalizumabreceptorreceptor bindingscreeningtherapeutic developmenttherapeutic target
项目摘要
Project Summary
The majority of allergic reactions are caused by anti-allergen IgE antibodies, which sensitize allergic effector
cells such as mast cells and basophils. In contrast to IgG antibodies, IgE binds with subnanomolar affinity to
the high affinity IgE receptor (FceRI) and persists in a receptor-bound form on allergic effector cells for months
even in the presence of high affinity anti-IgE antibody inhibitors, such as omalizumab. We have shown that
both antibodies and Designed Ankyrin Repeat Proteins (DARPins) are able to kinetically accelerate the
dissociation of IgE from FceRI through two mechanisms: a facilitated dissociation mechanism that allows
receptor-adjacent inhibitors to promote receptor dissociation and an allosteric mechanism that restricts IgE to a
conformation incompatible with receptor binding. We have developed a yeast display approach to selecting
anti-IgE inhibitors capable of disrupting receptor complexes and demonstrated our ability to select more potent
anti-IgE variants of omalizumab. In addition, we have demonstrated pathways to engineering more potent
bivalent disruptive inhibitors consisting of a disruptive anti-IgE domain and a non-competitive IgE anchoring
domain. Here we propose to apply these approaches to interrogate an anti-IgE immune library, to isolate more
potent disruptive inhibitors, to explore the mechanistic diversity of disruptive inhibitors and to develop
ultrapotent bivalent anti-IgE inhibitors compatible with future clinical development.
项目摘要
大多数过敏反应是由抗过敏原IgE抗体引起的,它能使过敏效应器致敏。
肥大细胞和嗜碱性粒细胞等细胞。与免疫球蛋白抗体不同,免疫球蛋白E以亚纳摩尔亲和力结合
高亲和力IgE受体(FceRI)在变态反应效应细胞上以受体结合的形式存在数月
即使在存在高亲和力的抗IgE抗体抑制剂的情况下,如奥马珠单抗。我们已经证明了
抗体和设计的Ankyrin重复蛋白(DARPins)都能够动力学地加速
IgE通过两种机制从FceRI解离:促进解离机制,允许
受体相邻抑制剂促进受体解离和变构机制将IgE限制为
构象与受体结合不相容。我们已经开发了一种酵母展示方法来选择
抗IgE抑制剂能够破坏受体复合体,并表明我们有能力选择更有效的
奥马珠单抗的抗IgE变异体。此外,我们还展示了工程设计更有效的途径
由干扰性抗IgE结构域和非竞争性IgE锚定组成的双价干扰性抑制剂
域。在这里,我们建议应用这些方法来询问抗IgE免疫库,以分离更多
有效的破坏性抑制剂,探索破坏性抑制剂的机理多样性并开发
与未来临床发展相适应的超强双价抗IgE抑制剂。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Theodore S Jardetzky其他文献
Theodore S Jardetzky的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Theodore S Jardetzky', 18)}}的其他基金
Discovery and engineering of novel anti-IgE disruptive inhibitors
新型抗 IgE 破坏性抑制剂的发现和工程设计
- 批准号:
10353982 - 财政年份:2021
- 资助金额:
$ 19.68万 - 项目类别:
Human Cytomegalovirus Entry into Cells Mediated by Pentamer and Trimer Complexes
五聚体和三聚体复合物介导的人巨细胞病毒进入细胞
- 批准号:
10468251 - 财政年份:2020
- 资助金额:
$ 19.68万 - 项目类别:
Human Cytomegalovirus Entry into Cells Mediated by Pentamer and Trimer Complexes
五聚体和三聚体复合物介导的人巨细胞病毒进入细胞
- 批准号:
10687819 - 财政年份:2020
- 资助金额:
$ 19.68万 - 项目类别:
Human Cytomegalovirus Entry into Cells Mediated by Pentamer and Trimer Complexes
五聚体和三聚体复合物介导的人巨细胞病毒进入细胞
- 批准号:
10120270 - 财政年份:2020
- 资助金额:
$ 19.68万 - 项目类别:
Human Cytomegalovirus Entry into Cells Mediated by Pentamer and Trimer Complexes
五聚体和三聚体复合物介导的人巨细胞病毒进入细胞
- 批准号:
10265549 - 财政年份:2020
- 资助金额:
$ 19.68万 - 项目类别:
Repertoire studies of human antibodies to RSV and MPV F
RSV 和 MPV F 人类抗体的谱研究
- 批准号:
10249184 - 财政年份:2018
- 资助金额:
$ 19.68万 - 项目类别:
Suppression of basophil activation by IgE glycovariants
IgE 糖变体抑制嗜碱性粒细胞活化
- 批准号:
9900056 - 财政年份:2018
- 资助金额:
$ 19.68万 - 项目类别:
Suppression of basophil activation by IgE glycovariants
IgE 糖变体抑制嗜碱性粒细胞活化
- 批准号:
10091046 - 财政年份:2018
- 资助金额:
$ 19.68万 - 项目类别:
相似海外基金
Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
- 批准号:
23H01982 - 财政年份:2023
- 资助金额:
$ 19.68万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
- 批准号:
23KJ0116 - 财政年份:2023
- 资助金额:
$ 19.68万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
- 批准号:
10682794 - 财政年份:2023
- 资助金额:
$ 19.68万 - 项目类别:
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
- 批准号:
10598276 - 财政年份:2023
- 资助金额:
$ 19.68万 - 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233343 - 财政年份:2023
- 资助金额:
$ 19.68万 - 项目类别:
Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233342 - 财政年份:2023
- 资助金额:
$ 19.68万 - 项目类别:
Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
- 批准号:
479363 - 财政年份:2023
- 资助金额:
$ 19.68万 - 项目类别:
Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
- 批准号:
10681989 - 财政年份:2023
- 资助金额:
$ 19.68万 - 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
- 批准号:
2237240 - 财政年份:2023
- 资助金额:
$ 19.68万 - 项目类别:
Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
- 批准号:
2305592 - 财政年份:2023
- 资助金额:
$ 19.68万 - 项目类别:
Continuing Grant